Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Heidi Taipale, Arto Puranen, Ellenor Mittendorfer-Rutz, Jari Tiihonen, Antti Tanskanen, Simon Cervenka & Markku Lähteenvuo. (2021) Antipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences. Nordic Journal of Psychiatry 75:5, pages 315-322.
Read now
Read now
Giuseppe Miscio, Giulia Paroni, Paola Bisceglia, Carolina Gravina, Maria Urbano, Madia Lozupone, Carla Piccininni, Michele Prisciandaro, Grazia Ciavarella, Antonio Daniele, Antonello Bellomo, Francesco Panza, Lazzaro Di Mauro, Antonio Greco & Davide Seripa. (2019) Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline. Expert Opinion on Drug Metabolism & Toxicology 15:9, pages 751-765.
Read now
Read now
Articles from other publishers (29)
Mujeeb U. Shad. (2023) Pharmacogenomic screening for agranulocytosis and efficacy with clozapine. Journal of Translational Genetics and Genomics 7:3, pages 141-65.
Crossref
Crossref
Regina F. Nasyrova, Elena E. Vaiman, Vera V. Repkina, Aiperi K. Khasanova, Azat R. Asadullin, German A. Shipulin, Kuanysh S. Altynbekov, Mustafa Al-Zamil, Marina M. Petrova & Natalia A. Shnayder. (2023) Single-Nucleotide Polymorphisms as Biomarkers of Antipsychotic-Induced Akathisia: Systematic Review. Genes 14:3, pages 616.
Crossref
Crossref
Wenjing Zhang, John A. Sweeney, Jeffrey R. Bishop, Qiyong Gong & Su Lui. (2023) Biological subtyping of psychiatric syndromes as a pathway for advances in drug discovery and personalized medicine. Nature Mental Health 1:2, pages 88-99.
Crossref
Crossref
Octavian Vasiliu. (2023) The pharmacogenetics of the new-generation antipsychotics – A scoping review focused on patients with severe psychiatric disorders. Frontiers in Psychiatry 14.
Crossref
Crossref
Lubna Tariq, Shabhat Rasool, Azher Arafah, Nouroz Sehar, Bisma Nisar, Bashayr Alsuwayni, Muneeb U. Rehman & Kaisar Bhat. 2023. Pharmacogenomics. Pharmacogenomics
97
111
.
Julia E. H. Brown, Jennifer L. Young & Nicole Martinez-Martin. (2022) Psychiatric genomics, mental health equity, and intersectionality: A framework for research and practice. Frontiers in Psychiatry 13.
Crossref
Crossref
Qingqing Xu, Yaojing Li, Mo Li, Shengying Qin, Ailing Ning, Ruixue Yuan, Yingmei Fu, Dongxiang Wang, Ran Zhang, Duan Zeng, Wenjuan Yu, Huafang Li & Shunying Yu. (2022)
The influence of
TNIK
gene polymorphisms on risperidone response in a Chinese Han population
. Pharmacogenomics 23:10, pages 575-583.
Crossref
Crossref
Elena Marcos-Vadillo, Lorena Carrascal-Laso, Ignacio Ramos-Gallego, Andrea Gaedigk, Belén García-Berrocal, Eduardo Mayor-Toranzo, Alfonso Sevillano-Jiménez, Almudena Sánchez, María Isidoro-García & Manuel Franco-Martín. (2022) Case Report: Pharmacogenetics Applied to Precision Psychiatry Could Explain the Outcome of a Patient With a New CYP2D6 Genotype. Frontiers in Psychiatry 12.
Crossref
Crossref
Brisa S. Fernandes, Alexandre Paim Diaz, João Quevedo, Lokesh Shahani, Marsal Sanches & Jair C. Soares. 2022. Biomarkers in Bipolar Disorders. Biomarkers in Bipolar Disorders
483
496
.
Paula Soria-Chacartegui, Gonzalo Villapalos-García, Pablo Zubiaur, Francisco Abad-Santos & Dora Koller. (2021) Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone. Frontiers in Pharmacology 12.
Crossref
Crossref
Sahar A. JallaqMark VerbaJeffrey R. StrawnLisa J. MartinMelissa P. DelBelloLaura B. Ramsey. (2021) CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders. Journal of Child and Adolescent Psychopharmacology 31:1, pages 56-62.
Crossref
Crossref
D. V. Ivashchenko, A. S. Osipov, E. V. Nazarova, M. A. Ovchinnikova, N. I. Buromskaya, V. V. Smirnov, P. V. Shimanov, R. V. Deitch, T. A. Fainshtein, E. N. Shagovenko, K. A. Akmalova, A. A. Kachanova, E. A. Grishina, L. M. Savchenko, Yu. S. Shevchenko & D. A. Sychev. (2020) Efficacy and safety of antipsychotics in adolescents with an acute psychotic episode in relation to the activity of CYP3A and CYP2D6 isoenzymes. Neurology, Neuropsychiatry, Psychosomatics 12:6, pages 11-18.
Crossref
Crossref
Dmitriy V. Ivashchenko, Sofi Z. Khoang, Bakhu V. Makhmudova, Nina I. Buromskaya, Pavel V. Shimanov, Roman V. Deitch, Kristina A. Akmalova, Grigoriy N. Shuev, Irina V. Dorina, Marina I. Nastovich, Eugenia N. Shagovenko, Elena A. Grishina, Lyudmila M. Savchenko, Yuriy S. Shevchenko & Dmitriy A. Sychev. (2020) Pharmacogenetics of antipsychotics in adolescents with acute psychotic episode during first 14 days after admission: effectiveness and safety evaluation. Drug Metabolism and Drug Interactions 35:4.
Crossref
Crossref
Jason M Noel & Cherry W Jackson. (2020) ASHP Therapeutic Position Statement on the Use of Antipsychotic Medications in the Treatment of Adults with Schizophrenia and Schizoaffective Disorder. American Journal of Health-System Pharmacy 77:24, pages 2114-2132.
Crossref
Crossref
Alfredo B. Cuéllar-Barboza, Susan L. McElroy, Marin Veldic, Balwinder Singh, Simon Kung, Francisco Romo-Nava, Nicolas A. Nunez, Alejandra Cabello-Arreola, Brandon J. Coombes, Miguel Prieto, Hannah K. Betcher, Katherine M. Moore, Stacey J. Winham, Joanna M. Biernacka & Mark A. Frye. (2020) Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection. International Journal of Bipolar Disorders 8:1.
Crossref
Crossref
Ina Liko, Erika Lai, Rachel J. Griffin, Christina L. Aquilante & Yee Ming Lee. (2020) Patients’ Perspectives on Psychiatric Pharmacogenetic Testing. Pharmacopsychiatry 53:06, pages 256-261.
Crossref
Crossref
D. V. Ivashchenko, S. Z. Khoang, M. Kh. Tazagulova, B. V. Makhmudova, N. I. Buromskaya, P. V. Shimanov, R. V. Deitch, I. V. Dorina, M. I. Nastovich, K. A. Akmalova, A. A. Kachanova, E. A. Grishina, L. M. Savchenko, Yu. S. Shevchenko & D. A. Sychev. (2020) The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot study. Neurology, Neuropsychiatry, Psychosomatics 12:5, pages 24-31.
Crossref
Crossref
Tatiana Zhiganova, Radkova Eugenia, Sergeeva Tatiana & Volovnikova Viktoriia. (2020) Differences in MDR1 (C3435T), CYP2D6, and CYP1A2 Genotype Frequencies between Patients with Treatment Failure to Antipsychotics and Healthy Russian Population. Current Pharmacogenomics and Personalized Medicine 17:1, pages 55-63.
Crossref
Crossref
Kyle J. Burghardt, Audrey S. Khoury, Zaher Msallaty, Zhengping Yi & Berhane Seyoum. (2020) Antipsychotic Medications and DNA Methylation in Schizophrenia and Bipolar Disorder: A Systematic Review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 40:4, pages 331-342.
Crossref
Crossref
Mary V. Seeman. (2020) Men and women respond differently to antipsychotic drugs. Neuropharmacology 163, pages 107631.
Crossref
Crossref
Naveen M, Amol N. Patil, Smita Pattanaik, Anit Kaur, Dibyajyoti Banerjee & Sandeep Grover. (2020) ABCB1 and DRD3 polymorphism as a response predicting biomarker and tool for pharmacogenetically guided clozapine dosing in Asian Indian treatment resistant schizophrenia patients. Asian Journal of Psychiatry 48, pages 101918.
Crossref
Crossref
Jonathan C.W. Liu, Ilona Gorbovskaya, Chad Bousman, Lisa C. Brown & Daniel J. Müller. 2020. Personalized Psychiatry. Personalized Psychiatry
449
457
.
Yin Cheong Wong, Maddalena Centanni & Elizabeth C. M. de Lange. (2019) Physiologically Based Modeling Approach to Predict Dopamine D2 Receptor Occupancy of Antipsychotics in Brain: Translation From Rat to Human. The Journal of Clinical Pharmacology 59:5, pages 731-747.
Crossref
Crossref
Josiah D Allen & Jeffrey R Bishop. (2019) A systematic review of genome-wide association studies of antipsychotic response. Pharmacogenomics 20:4, pages 291-306.
Crossref
Crossref
Shusuke Numata, Hidehiro Umehara, Tetsuro Ohmori & Ryota Hashimoto. (2018) Clozapine Pharmacogenetic Studies in Schizophrenia: Efficacy and Agranulocytosis. Frontiers in Pharmacology 9.
Crossref
Crossref
Myrto T Samara, Elisabeth Klupp, Bartosz Helfer, Philipp H Rothe, Johannes Schneider-Thoma & Stefan Leucht. (2018) Increasing antipsychotic dose for non response in schizophrenia. Cochrane Database of Systematic Reviews 2018:5.
Crossref
Crossref
Babu Swathy, Koramannil R Saradalekshmi, Indu V Nair, Chandrasekharan Nair & Moinak Banerjee. (2018) Understanding the influence of antipsychotic drugs on global methylation events and its relevance in treatment response. Epigenomics 10:3, pages 233-247.
Crossref
Crossref
Seenae Eum, Mark E. Schneiderhan, Jacob T. Brown, Adam M. Lee & Jeffrey R. Bishop. (2017) Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report. BMC Psychiatry 17:1.
Crossref
Crossref
René Zeiss, Bernhard J. Connemann & Maximilian Gahr. (2017) Metabolische Nebenwirkungen von Psychopharmaka. DNP - Der Neurologe & Psychiater 18:3, pages 44-52.
Crossref
Crossref